Literature DB >> 20138540

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Otto Metzger Filho1, Michail Ignatiadis, Christos Sotiriou.   

Abstract

Different multi-gene expression signatures have been shown to outperform classic histopathologic variables and therefore represent an important step towards personalizing breast cancer treatment. In particular, gene profiles overcome many of the limitations observed with classic histopathologic variables. The Genomic Grade Index (GGI) is a gene expression signature developed to better define histologic grade assessment. GGI divides classic histologic grade into low and high risk, instead of grades 1, 2 and 3. The ability of GGI to predict response to chemotherapy and separate hormone receptor positive breast cancer subtypes has also been demonstrated. This article critically reviews the limitations inherent in classic histologic grade evaluation; it also reviews the process of gene signature development in general and then focuses on GGI, its biologic significance, comparison with different gene signatures, and its applicability to clinical practise. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 20138540     DOI: 10.1016/j.critrevonc.2010.01.011

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  14 in total

Review 1.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

Review 2.  The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.

Authors:  Kathleen Van Asten; An Poppe; Kevin Punie; Lynn Jongen; Anneleen Lintermans; Hans Wildiers; Patrick Neven
Journal:  Curr Treat Options Oncol       Date:  2015-07

3.  Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

Authors:  Catherine M Kelly; Philip S Bernard; Savitri Krishnamurthy; Bailiang Wang; Mark T W Ebbert; Roy R L Bastien; Kenneth M Boucher; Elliana Young; Takayuki Iwamoto; Lajos Pusztai
Journal:  Oncologist       Date:  2012-03-14

Review 4.  Metastasis dormancy in estrogen receptor-positive breast cancer.

Authors:  Xiang H-F Zhang; Mario Giuliano; Meghana V Trivedi; Rachel Schiff; C Kent Osborne
Journal:  Clin Cancer Res       Date:  2013-12-01       Impact factor: 12.531

Review 5.  Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.

Authors:  Vida Pourteimoor; Samira Mohammadi-Yeganeh; Mahdi Paryan
Journal:  Tumour Biol       Date:  2016-09-20

6.  High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.

Authors:  Abdelbaset Buhmeida; Ashraf Dallol; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Fatima Al-Thubaity; Mohammed H Al-Qahtani
Journal:  Tumour Biol       Date:  2013-11-19

7.  The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain.

Authors:  Rajendra P Pangeni; Prasanna Channathodiyil; David S Huen; Lawrence W Eagles; Balraj K Johal; Dawar Pasha; Natasa Hadjistephanou; Oliver Nevell; Claire L Davies; Ayobami I Adewumi; Hamida Khanom; Ikroop S Samra; Vanessa C Buzatto; Preethi Chandrasekaran; Thoraia Shinawi; Timothy P Dawson; Katherine M Ashton; Charles Davis; Andrew R Brodbelt; Michael D Jenkinson; Ivan Bièche; Farida Latif; John L Darling; Tracy J Warr; Mark R Morris
Journal:  Clin Epigenetics       Date:  2015-05-27       Impact factor: 6.551

8.  Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.

Authors:  Otto Metzger-Filho; Aurélie Catteau; Stefan Michiels; Marc Buyse; Michail Ignatiadis; Kamal S Saini; Evandro de Azambuja; Virginie Fasolo; Sihem Naji; Jean Luc Canon; Paul Delrée; Michel Coibion; Pino Cusumano; Veronique Jossa; Jean Pierre Kains; Denis Larsimont; Vincent Richard; Daniel Faverly; Nathalie Cornez; Peter Vuylsteke; Brigitte Vanderschueren; Hélène Peyro-Saint-Paul; Martine Piccart; Christos Sotiriou
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

9.  Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.

Authors:  Claudia Cava; Gloria Bertoli; Marilena Ripamonti; Giancarlo Mauri; Italo Zoppis; Pasquale Anthony Della Rosa; Maria Carla Gilardi; Isabella Castiglioni
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

10.  Decreased expression of C10orf10 and its prognostic significance in human breast cancer.

Authors:  Junjiang Deng; Yan Dong; Chong Li; Wenwei Zuo; Gang Meng; Chengping Xu; Jianjun Li
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.